International Business Watch
SEE OTHER BRANDS

Get your business and economy news from the world

Dr. Majid Alfayyadh At FII: Saudi Arabia’s in-House CAR-T Manufacturing Signals Readiness to Lead Biotech’s Next Era

RIYADH, SAUDI ARABIA, October 31, 2025 /EINPresswire.com/ -- Dr. Majid Alfayyadh, CEO of King Faisal Specialist Hospital & Research Centre (KFSHRC), said, at the Future Investment Initiative, the hospital’s in-house manufacturing and clinical use of CAR-T cell therapy marks a major shift in localizing advanced treatments and shows the Kingdom is ready to adopt world-class therapeutic technologies.

Speaking on the panel “Which Markets Will Build the Next Biotech Megaclusters?”, he noted that this milestone reflects the rapid growth of Saudi research and clinical capability and KFSHRC’s role as a catalyst for innovation and a regional hub for biotechnology. He added that the hospital is strengthening its research and biomanufacturing ecosystem in line with national priorities in precision medicine and gene therapy.

Dr. Alfayyadh emphasized that Saudi Arabia’s biotech transformation is driven by an ambitious national vision to become a global medical-innovation hub by 2040, supported by integrated research, regulatory, and investment environment that attracts leading global partners.

The CEO highlighted accelerated regulatory progress, including the Saudi Food and Drug Authority’s clinical-trial approvals in as little as 60 days, as evidence of effective governance and a strong climate for research and innovation.

He added that building an advanced biotech sector relies on modern infrastructure, sustained investment, and flexible regulation that speeds up innovation and turns research into medical and commercial applications, noting that integration across research, development, clinical trials, and commercialization is the foundation for growing the Kingdom’s biotechnology sector.

According to Dr. Alfayyadh, international collaboration is a central pillar of this sector’s development, with the Kingdom forging strategic partnerships with leading research centers and global companies to exchange knowledge and transfer technology, strengthening its presence in the global bio-innovation and biomanufacturing ecosystem and advancing Vision 2030 goals to localize biopharma and grow the knowledge economy.

National talent, he concluded, is the cornerstone of a sustainable biotech sector, noting that the Kingdom continues to invest in a new generation of scientists and researchers through scholarships and specialized training, alongside the imminent launch of a national GMP-compliant facility within the next two years, strengthening Saudi Arabia’s bio-self-sufficiency and enabling an innovation-driven healthcare economy.

KFSHRC has been ranked first in the Middle East and North Africa and fifteenth globally among the world’s top 250 academic medical centers for 2025 and recognized by Brand Finance as the region’s most valuable healthcare brand. It is also listed among Newsweek’s World’s Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026, reaffirming its leadership in innovation-driven care.

Riyadh
King Faisal Specialist Hospital & Research Centre
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions